🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 21 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 08/08/2013 | 78,42 | 78,42 | 77,22 | 77,67 | -0,49% | 1,53% | 707.500 |
| 07/08/2013 | 77,31 | 78,52 | 76,80 | 78,05 | +0,93% | 2,22% | 974.400 |
| 06/08/2013 | 78,66 | 78,98 | 76,86 | 77,33 | -2,10% | 2,70% | 930.700 |
| 05/08/2013 | 79,49 | 79,81 | 78,03 | 78,99 | -0,57% | 2,24% | 1.036.500 |
| 02/08/2013 | 80,68 | 81,21 | 78,52 | 79,44 | -1,59% | 3,33% | 1.319.800 |
| 01/08/2013 | 80,59 | 81,98 | 80,26 | 80,72 | +1,15% | 2,13% | 2.086.300 |
| 31/07/2013 | 82,37 | 83,24 | 79,65 | 79,80 | -2,58% | 4,36% | 2.060.900 |
| 30/07/2013 | 81,49 | 85,72 | 81,00 | 81,91 | +2,82% | 5,79% | 3.692.700 |
| 29/07/2013 | 79,99 | 81,34 | 79,13 | 79,66 | -1,30% | 2,76% | 1.588.000 |
| 26/07/2013 | 80,22 | 82,20 | 79,60 | 80,71 | -7,89% | 3,24% | 4.072.300 |
| 25/07/2013 | 84,77 | 87,89 | 84,00 | 87,62 | +2,77% | 4,59% | 1.281.300 |
| 24/07/2013 | 86,95 | 87,48 | 84,50 | 85,26 | -1,49% | 3,43% | 1.293.600 |
| 23/07/2013 | 87,95 | 88,81 | 86,28 | 86,55 | -1,92% | 2,88% | 1.219.100 |
| 22/07/2013 | 89,01 | 89,36 | 87,00 | 88,24 | -0,31% | 2,65% | 1.805.100 |
| 19/07/2013 | 86,99 | 89,96 | 86,70 | 88,51 | +1,98% | 3,75% | 2.228.700 |
| 18/07/2013 | 85,99 | 86,93 | 85,10 | 86,79 | +1,50% | 2,13% | 715.600 |
| 17/07/2013 | 85,20 | 86,80 | 85,20 | 85,51 | +0,02% | 1,88% | 804.400 |
| 16/07/2013 | 86,42 | 87,00 | 84,98 | 85,49 | -1,45% | 2,34% | 1.124.400 |
| 15/07/2013 | 87,09 | 87,63 | 85,66 | 86,75 | -1,18% | 2,26% | 1.079.000 |
| 12/07/2013 | 84,55 | 88,00 | 83,29 | 87,79 | +3,65% | 5,57% | 2.087.100 |
| 11/07/2013 | 82,05 | 84,78 | 81,86 | 84,70 | +3,75% | 3,56% | 1.475.900 |
| 10/07/2013 | 80,10 | 81,73 | 79,76 | 81,64 | +2,06% | 2,46% | 1.161.100 |
| 09/07/2013 | 80,71 | 82,00 | 79,01 | 79,99 | -0,49% | 3,70% | 1.069.600 |
| 08/07/2013 | 83,25 | 83,25 | 80,01 | 80,38 | -2,49% | 3,89% | 915.300 |
| 05/07/2013 | 81,21 | 82,48 | 80,17 | 82,43 | +2,23% | 2,84% | 696.800 |
| 03/07/2013 | 79,63 | 80,86 | 79,06 | 80,63 | +1,40% | 2,26% | 863.200 |
| 02/07/2013 | 80,60 | 81,88 | 78,82 | 79,52 | -1,13% | 3,80% | 1.620.300 |
| 01/07/2013 | 81,44 | 85,47 | 80,30 | 80,43 | +0,46% | 6,35% | 2.012.800 |
| 28/06/2013 | 80,20 | 81,38 | 79,54 | 80,06 | -0,58% | 2,29% | 2.204.400 |
| 27/06/2013 | 81,56 | 81,77 | 79,66 | 80,53 | +0,26% | 2,59% | 1.074.800 |